NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, announces participation in two investor conferences this November. Hyung Heon Kim, President and CEO, and Marshall H. Woodworth, CFO, will present company overviews at the Life Science Virtual Investor Forum on November 14 at 1:00 pm ET and the Winter 2024 Investor Summit Virtual on November 21 at 11:00 am ET. Management will be available for one-on-one meetings during both events. Interested parties can register through provided links or contact Michael Miller for meetings outside these events.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), un'azienda biotecnologica in fase clinica focalizzata sulle malattie cardiometaboliche, annuncia la partecipazione a due conferenze per investitori questo novembre. Hyung Heon Kim, Presidente e CEO, e Marshall H. Woodworth, CFO, presenteranno una panoramica dell'azienda al Life Science Virtual Investor Forum il 14 novembre alle 13:00 ET e al Winter 2024 Investor Summit Virtual il 21 novembre alle 11:00 ET. La direzione sarà disponibile per incontri individuali durante entrambi gli eventi. Gli interessati possono registrarsi attraverso i link forniti o contattare Michael Miller per incontri al di fuori di questi eventi.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), una empresa de biotecnología en fase clínica centrada en las enfermedades cardiometabólicas, anuncia su participación en dos conferencias para inversores este noviembre. Hyung Heon Kim, Presidente y CEO, y Marshall H. Woodworth, CFO, presentarán una visión general de la empresa en el Life Science Virtual Investor Forum el 14 de noviembre a la 1:00 pm ET y en el Winter 2024 Investor Summit Virtual el 21 de noviembre a las 11:00 am ET. La dirección estará disponible para reuniones uno a uno durante ambos eventos. Las partes interesadas pueden registrarse a través de los enlaces proporcionados o contactar a Michael Miller para reuniones fuera de estos eventos.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), 심혈관 대사 질환에 주력하는 임상 단계의 생명공학 회사가 이번 11월에 두 개의 투자자 회의에 참여한다고 발표했습니다. Hyung Heon Kim 이사장 겸 CEO, Marshall H. Woodworth CFO가 11월 14일 오후 1시 ET에 Life Science Virtual Investor Forum에서 회사 개요를 발표하며, 11월 21일 오전 11시 ET에 Winter 2024 Investor Summit Virtual에서도 발표할 예정입니다. 경영진은 두 이벤트 동안 일대일 미팅이 가능합니다. 관심 있는 분들은 제공된 링크를 통해 등록하거나 외부 미팅을 위해 Michael Miller에게 연락할 수 있습니다.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), une entreprise biopharmaceutique en phase clinique axée sur les maladies cardiométaboliques, annonce sa participation à deux conférences pour investisseurs en novembre. Hyung Heon Kim, Président et PDG, et Marshall H. Woodworth, CFO, présenteront un aperçu de l'entreprise lors du Life Science Virtual Investor Forum le 14 novembre à 13h00 ET et lors du Winter 2024 Investor Summit Virtual le 21 novembre à 11h00 ET. La direction sera disponible pour des réunions individuelles pendant les deux événements. Les parties intéressées peuvent s'inscrire via les liens fournis ou contacter Michael Miller pour des réunions en dehors de ces événements.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf kardiometabolischen Erkrankungen, gibt die Teilnahme an zwei Investorenkonferenzen im November bekannt. Hyung Heon Kim, Präsident und CEO, und Marshall H. Woodworth, CFO, werden am 14. November um 13:00 Uhr ET auf dem Life Science Virtual Investor Forum einen Unternehmensüberblick präsentieren und am 21. November um 11:00 Uhr ET auf dem Winter 2024 Investor Summit Virtual. Das Management steht während beider Veranstaltungen für Einzelgespräche zur Verfügung. Interessierte Parteien können sich über die bereitgestellten Links registrieren oder Michael Miller für Treffen außerhalb dieser Veranstaltungen kontaktieren.
- None.
- None.
- November 14: Life Science Virtual Investor Forum. Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Thursday, November 14, at 1:00 pm ET. Management will also be available for one-on-one meetings during the event. Interested parties who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference at https://www.virtualinvestorconferences.com/events/event-details/life-sciences-investor-forum-6.
- November 21: Winter 2024 Investor Summit Virtual. Mr. Kim and Mr. Woodworth will present a company overview on Thursday, November 21, at 11:00 am ET, at this virtual summit. To listen to the presentation or to schedule one-on-one meetings, interested parties can register at: https://www.webcaster4.com/Webcast/Page/3075/51588.
To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.
For more information, please visit www.neurobopharma.com.
Contacts:
NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-november-302303033.html
SOURCE NeuroBo Pharmaceuticals, Inc.
FAQ
When is NeuroBo Pharmaceuticals (NRBO) presenting at the Life Science Virtual Investor Forum?
What investor conferences is NeuroBo Pharmaceuticals (NRBO) attending in November 2024?
How can investors schedule meetings with NeuroBo Pharmaceuticals (NRBO) management?
What time is NeuroBo Pharmaceuticals (NRBO) presenting at the Winter 2024 Investor Summit?
